Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America

In a high percentage of patients with chronic kidney disease (CKD) low levels of vitamin D are detected. The purpose of this study was to evaluate if the native vitamin D therapy (cholecalciferol) in the patients with stage 3 and hypovitaminosis D allows to modify markers of bone and mineral metabol...

Full description

Autores:: Restrepo Valencia, Cesar A.
Aguirre Arango, Jose V.
Musso, Carlos G.

Tipo de recurso:

Fecha de publicación:: 2019

Institución:: Universidad Simón Bolívar

Repositorio:: Repositorio Digital USB

Idioma:: eng

id	USIMONBOL2_44c05e2a1bf2a9492f0251b1a1a210d1
oai_identifier_str	oai:bonga.unisimon.edu.co:20.500.12442/4533
network_acronym_str	USIMONBOL2
network_name_str	Repositorio Digital USB
repository_id_str
dc.title.eng.fl_str_mv	Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America
title	Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America
spellingShingle	Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America Vitamin D Cholecalciferol Chronic kidney disease Hypovitaminosis D
title_short	Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America
title_full	Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America
title_fullStr	Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America
title_full_unstemmed	Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America
title_sort	Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America
dc.creator.fl_str_mv	Restrepo Valencia, Cesar A. Aguirre Arango, Jose V. Musso, Carlos G.
dc.contributor.author.none.fl_str_mv	Restrepo Valencia, Cesar A. Aguirre Arango, Jose V. Musso, Carlos G.
dc.subject.eng.fl_str_mv	Vitamin D Cholecalciferol Chronic kidney disease Hypovitaminosis D
topic	Vitamin D Cholecalciferol Chronic kidney disease Hypovitaminosis D
description	In a high percentage of patients with chronic kidney disease (CKD) low levels of vitamin D are detected. The purpose of this study was to evaluate if the native vitamin D therapy (cholecalciferol) in the patients with stage 3 and hypovitaminosis D allows to modify markers of bone and mineral metabolism once normal serum levels have been achieved.
publishDate	2019
dc.date.issued.none.fl_str_mv	2019
dc.date.accessioned.none.fl_str_mv	2020-01-17T14:39:23Z
dc.date.available.none.fl_str_mv	2020-01-17T14:39:23Z
dc.type.eng.fl_str_mv	article
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.identifier.issn.none.fl_str_mv	11787058
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/20.500.12442/4533
identifier_str_mv	11787058
url	https://hdl.handle.net/20.500.12442/4533
dc.language.iso.eng.fl_str_mv	eng
language	eng
dc.rights.eng.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.eng.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.spa.fl_str_mv	pdf
dc.publisher.eng.fl_str_mv	Dovepress
dc.source.eng.fl_str_mv	International Journal of Nephrology and Renovascular Disease
dc.source.none.fl_str_mv	Vol. 12 (2019)
institution	Universidad Simón Bolívar
dc.source.uri.none.fl_str_mv	https://doi.org/10.2147/IJNRD.S214194
bitstream.url.fl_str_mv	https://bonga.unisimon.edu.co/bitstreams/4f085007-1b93-4787-b451-e6a052837123/download https://bonga.unisimon.edu.co/bitstreams/2104209d-01e3-431c-8a52-972a96bbe8cb/download https://bonga.unisimon.edu.co/bitstreams/e70a7d11-6cb1-43c1-b22a-8c007684635d/download https://bonga.unisimon.edu.co/bitstreams/69aa94d4-9dc2-4be0-a13c-fb77ac044b62/download https://bonga.unisimon.edu.co/bitstreams/a409bae6-3e1e-4e36-8dbf-42f277ea4e10/download https://bonga.unisimon.edu.co/bitstreams/6a9563d3-5bde-4b14-aede-834d87eca5af/download https://bonga.unisimon.edu.co/bitstreams/8f3345e7-f918-4b2f-8446-f4402fb0d890/download
bitstream.checksum.fl_str_mv	a137b2c170f6b88daaf8fa269aee95dc 4460e5956bc1d1639be9ae6146a50347 733bec43a0bf5ade4d97db708e29b185 c80a6acf506b867161384f97069b8d1c 3ed9ff50e76ed1d366b73c3571118aaa 798a7f8668c299b3992eb95a13d045c3 3e45b140ed10a136b399022e9db284b4
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv	repositorio.digital@unisimon.edu.co
_version_	1812100491252858880
spelling	Restrepo Valencia, Cesar A.7751b67a-dc22-4a39-bd8f-733650c937acAguirre Arango, Jose V.70f1c568-c6c8-49c2-a303-321843d0ed06Musso, Carlos G.b310094b-baeb-4838-bde5-206ff47448242020-01-17T14:39:23Z2020-01-17T14:39:23Z201911787058https://hdl.handle.net/20.500.12442/4533In a high percentage of patients with chronic kidney disease (CKD) low levels of vitamin D are detected. The purpose of this study was to evaluate if the native vitamin D therapy (cholecalciferol) in the patients with stage 3 and hypovitaminosis D allows to modify markers of bone and mineral metabolism once normal serum levels have been achieved.pdfengDovepressAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/http://purl.org/coar/access_right/c_abf2International Journal of Nephrology and Renovascular DiseaseVol. 12 (2019)https://doi.org/10.2147/IJNRD.S214194Vitamin DCholecalciferolChronic kidney diseaseHypovitaminosis DEffectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South Americaarticlehttp://purl.org/coar/resource_type/c_6501Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8–F28. doi:10.1152/ajprenal.00336.2004Jones G. Extrarenal vitamin D activation and interactions between vitamin D2, vitamin D3, and vitamin D analogs. Annu Rev Nutr. 2013;33:10.1–10.22. doi:10.1146/annurev-nutr-071812-161203Michigami T. Update on recent progress in vitamin D research. Vitamin D metabolism and its regulation. Clin Calcium. 2017;27:1517–1523. doi:10.CliCa171115171523Wheeler DC, Winkelmayer WC. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59. doi:10.1016/j.kisu.2017.04.001Restrepo VCA, Aguirre AJV. Vitamin D (25(OH)D) in patients with chronic kidney disease stages 2–5. Colomb Med (Cali). 2016;47: 160–166. doi:10.25100/cm.v47i3.2148Restrepo VCA, Aguirre AJV, Caceres ED. Determination of vitamin D (25(OH)D) levels in renal transplant patients and their importance in accordance with the glomerular filtration rate. Rev Colomb Reumatol. 2018;25:161–168.Gluba-Brzozka A, Franczyk B, Cialkowska-Rysz C, Olszewski R, Rysz J. Impact of vitamin D on the cardiovascular system in advance chronic kidney disease (CKD) and dialysis patients. Nutrients. 2018;10:6: 709. doi:10.3390/nu10060709Zhang Y, Darssan D, Pascoe EM, Johnson DW, Pi H, Dong J. Vitamin D status and mortality risk among patients on dialysis: a systematic review and meta-analysis of observational studies. Nephrol Dial Transplant. 2018;33:1742–1751. doi:10.1093/ndt/gfy016Liu M, Wang J, He Y. Serum 25-Hydroxyvitamin D were associated with higher risk of both albuminuria and impaired GFR incidence: a cohort study based on CLHLS study. BMC Nephrol. 2019;20:20. doi:10.1186/s12882-019-1202-8Molina P, Gorriz JL, Molina MD, et al. What is the optimal level of vitamin D in non-dialysis chronic kidney disease population? World J Nephrol. 2016;5:471–481. doi:10.5527/wjn.v5.i5.471Eknoyan G, Levin A, Levin NW. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1–S202. doi:10.1016/S0272- 6386(03)00905-3KDIGO. Clinical practice for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorders (CKD-MBD). Kidney Int. 2009;76(suppl 113):S1–S130.Alola JF. Clinical review: the 2011 report on dietary reference intake for vitamin D: where do we go from here? J Clin Endocrinol Metab. 2011;96:2987–2996. doi:10.1210/jc.2011-0090Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842–856. doi:10.1093/ajcn/ 69.5.842Lee JP, Tansey M, Jetton JG, Krasowski MD. Vitamina D toxicity: a 16 year retrospective study at an academic medical center. Lab Med. 2018;21:123–129. doi:10.1093/labmed/lmx077Etayo HE, Restrepo CA. Acute tubular necrosis due to hypercalcemia secondary to vitamin D toxicity. Acta Med Colomb. 2010;35:99–102.Garcia CA, Holguin MC, Caceres D, Restrepo CA. Importance of hyperphosphatemia in chronic kidney disease, how to avoid it and treat it by nutritional measures. Rev Colomb Nefrol. 2017;4:24–41.Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988;67:929–936. doi:10.1210/jcem-67-5-929Toussaint ND, Damasiewicz MJ. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the arms? Nephrology (Carlton). 2017;22 (Suppl 2):51–56. doi:10.1111/nep.13026Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254. doi:10.7326/0003-4819-145-4-200608150-00004Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713–716. doi:10.1007/s00198-005-1867-7Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int. 2010;21:1151–1154. doi:10.1007/s00198-010-1285-3American geriatrics society workgroup on vitamin D supplementation for older adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for prevention of falls and their consequences. J Am Geriatr Soc. 2014;62:147–152. doi:10.1111/jgs.12631Lips P. Vitamin D status and nutrition in Europe and Asia. J Steroid Biochem Mol Biol. 2007;103:620–625. doi:10.1016/j.jsbmb.2006.12.076Fuleihan GE-H. Vitamin D deficiency in the Middle East and its health consequences for children and Adults. Clinic Rev Bone Miner Metab. 2009;7:77–93. doi:10.1007/s12018-009-9027-9Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20: 1807–1820. doi:10.1007/s00198-009-0954-6Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930. doi:10.1210/jc.2011- 0385Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439–443. doi:10.1007/s001980050030Vieth R, Ladak Y, Walfish PG. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab. 2003;88:185–191. doi:10.1210/jc.2002- 021064Dawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr. 1997;65:67–71. doi:10.1093/ajcn/ 65.1.67Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–58. doi:10.1210/jc.2010-2704Priemel M, von Domarus C, Klatte TO, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25:305–312. doi:10.1359/jbmr. 090728Shroff R, Wan M, Nagler EV, et al. Clinical practice recommendations for native vitamin D therapy in children with chronic kidney disease stages 2–5 and on dialysis. European society for paediatric nephrology chronic kidney disease mineral and bone disorders and dialysis working groups. Nephrol Dial Transplant. 2017;32: 1098–1113. doi:10.1093/ndt/gfx065Shroff R, Wan M, Gullett A, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol. 2012;7:216–223. doi:10.2215/CJN.04760511Krause R, Roth HJ, Kaase H, Stange R, Holick MF. Vitamin D status in chronic kidney disease – UVB irradiation is superior to oral supplementation. Anticancer Res. 2016;36:1397–1401.KDOQI WG. K/DOQI clinical practice guidelines for nutrition in children with CKD. Am J Kidney Dis. 2009;53:S11–S104.Fried C, Zitt E. Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2017;10:109–122. doi:10.2147/IJNRD. S97637Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2012;96:672–679. doi:10.3945/ajcn.112.040642Westerberg P-A, Sterner G, Ljunggren O, et al. High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD stages 3–4: results of a 12-week double-blind, randomized, controlled study. Nephrol Dial Transplant. 2018;33:466–471. doi:10.1093/ ndt/gfx059Yadav AK, Kumar V, Kumar V, Banerjee D, Gupta KL, Jha V. The effect of vitamin D supplementation on bone metabolic markers in chronic kidney disease. J Bone Miner Res. 2018;33:404–409. doi:10.1002/jbmr.v33.3Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007;50:59–68. doi:10.1053/j.ajkd.2007.04.010Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007;27:36–43. doi:10.1159/000098561Thimachai P, Supasyndh O, Chaiprasert A, Satirapoj B. Efficacy of high vs conventional ergocalciferol dose for increasing 25- hydroxyvitamin D and suppressing parathyroid hormone levels in stage III–IV CKD with vitamin D deficiency/insufficiency: a randomized controlled trial. J Med Assoc Thai. 2015;98:643–648.Tripkovic L, Lambert H, Hart K, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systemic review and meta-analysis. Am J Clin Nutr. 2012;95:1357–1364. doi:10.3945/ajcn.111.031070Wetmore JB, Kimber C, Mahnken JD, Stubbs JR. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. Br J Nutr. 2016;116:2074–2081. doi:10.1017/S000711451600427XTripkovic L, Wilson LR, Hart K, et al. Daily supplementation with 15 ug vitamin D2 compared with vitamin D3 to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: a 12 wk randomized, placebo-controlled food-fortification trial. Am J Clin Nutr. 2017;106:481–490. doi:10. 3945/ajcn.116.138693Oliveri B, Mastaglia SR, Brito GM, et al. Vitamin D3 seems more appropiate than D2 to sustain adequate levels of 25OHD: a pharmacokinetic approach. Eur J Clin Nutr. 2015;69:697–702. doi:10.1038/ejcn.2015.16Chao YS, Brunel L, Faris P, Veugelers PJ. The importance of dose, frequency and duration of vitamin D supplementation for plasma 25-hydroxyvitamin D. Nutrients. 2013;5:4067–4078. doi:10.3390/ nu5104067Mager D, Jackson ST, Hoffmann M, Jindal K, Senior PA. Vitamin D3 supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: results of an open label randomized clinical trial. Clin Nutr. 2017;36:686–696. doi:10.1016/j.clnu.2016. 05.012Bover J, Egido J, Fernandez-Giraldez E, et al. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease. Nefrologia. 2015;35:28–41. doi:10.3265/ Nefrologia.pre2014.Sep.11796Melamed ML, Chonchol M, Gutierre OM, et al. The role of vitamin D in CKD stages 3 to 4: report of a scientific workshop sponsored by the national kidney foundation. Am J Kidney Dis. 2018;72:834–845. doi:10.1053/j.ajkd.2018.06.031ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf404807https://bonga.unisimon.edu.co/bitstreams/4f085007-1b93-4787-b451-e6a052837123/downloada137b2c170f6b88daaf8fa269aee95dcMD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/2104209d-01e3-431c-8a52-972a96bbe8cb/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/e70a7d11-6cb1-43c1-b22a-8c007684635d/download733bec43a0bf5ade4d97db708e29b185MD53TEXTEffectivenessofNativeVitaminDTherapyin.pdf.txtEffectivenessofNativeVitaminDTherapyin.pdf.txtExtracted texttext/plain48529https://bonga.unisimon.edu.co/bitstreams/69aa94d4-9dc2-4be0-a13c-fb77ac044b62/downloadc80a6acf506b867161384f97069b8d1cMD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain53467https://bonga.unisimon.edu.co/bitstreams/a409bae6-3e1e-4e36-8dbf-42f277ea4e10/download3ed9ff50e76ed1d366b73c3571118aaaMD56THUMBNAILEffectivenessofNativeVitaminDTherapyin.pdf.jpgEffectivenessofNativeVitaminDTherapyin.pdf.jpgGenerated Thumbnailimage/jpeg1748https://bonga.unisimon.edu.co/bitstreams/6a9563d3-5bde-4b14-aede-834d87eca5af/download798a7f8668c299b3992eb95a13d045c3MD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5847https://bonga.unisimon.edu.co/bitstreams/8f3345e7-f918-4b2f-8446-f4402fb0d890/download3e45b140ed10a136b399022e9db284b4MD5720.500.12442/4533oai:bonga.unisimon.edu.co:20.500.12442/45332024-08-14 21:53:08.94http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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

Effectiveness of native vitamin D therapy in patients with chronic kidney disease stage 3 and hypovitaminosis D in Colombia, South America

Publicaciones similares